Ten head-to-head clinical trials — pulled from the GreenMedInfo archive — in which honey, turmeric, saffron, ginger and a handful of other kitchen staples matched or outperformed prescription medications. Each one links to the full research write-up.

By Sayer Ji | October 4, 2026

For nearly two decades, GreenMedInfo has done one thing most health publishers never bother with: we go into the National Library of Medicine and pull out the studies where researchers put a natural substance directly against a drug — same condition, same patients, same scoring — and then publish what they found.

Those studies exist. There are thousands of them. They just don’t get press releases, because nobody holds a patent on honey.

Below are ten of the most striking. Every one is a human trial. Every one is indexed in our database. And every one links to the long-form article where you can read the methodology, the numbers and the citations for yourself.

A word before we start: this is research information, not medical advice. Several of these trials are small. Some are single studies that have not been replicated. I have flagged which ones have the strongest designs. Read them, bring them to your practitioner, and decide for yourself. That is the entire point of having the archive.

1. Honey + Coffee vs. Prednisolone — Persistent Cough

 

The trial: Randomized, double-blind, 97 adults with post-infectious cough lasting more than three weeks. One group got a paste of honey and instant coffee every eight hours. One got the steroid prednisolone. One got guaifenesin (the active ingredient in Mucinex). Primary Care Respiratory Journal, 2013.

The result: Cough scores in the honey-coffee group fell from 2.9 to 0.2 — a 93% reduction. Prednisolone managed 3.0 to 2.4, about 20%. Guaifenesin did essentially nothing. The study authors’ own conclusion: “Honey plus coffee was found to be the most effective treatment modality.”

A kitchen remedy outperformed a corticosteroid by a factor of roughly fourteen — with none of the steroid’s immune-suppressing, bone-thinning, blood-sugar-wrecking side effects.

→ Read the full article: A Spoonful of Honey and Coffee Did What Prednisone Couldn’t

2. Curcumin vs. Metformin — Stopping Prediabetes Cold

 

The trial: Randomized controlled trial in Thailand, published in the American Diabetes Association’s own journal, Diabetes Care, 2012. Prediabetic patients took either a curcumin extract (from turmeric) or placebo for nine months.

The result: Zero patients in the curcumin group progressed to type 2 diabetes. In the placebo group, 16.4% did. Curcumin also improved beta-cell function and reduced insulin resistance, with only minor side effects reported.

For context: metformin, the front-line drug given to high-risk patients, reduced progression to diabetes by just 31% over three years in the landmark Diabetes Prevention Program. No pharmaceutical has ever come close to a 100% prevention rate.

→ Read the full article: 100% Diabetes Prevention Achieved Naturally

3. Berberine vs. Metformin — Type 2 Diabetes

 

The trial: 36 adults with newly diagnosed type 2 diabetes, three months, berberine versus metformin head-to-head. Metabolism, 2008.

The result: Berberine — a bitter alkaloid from goldenseal, barberry and Oregon grape — matched metformin on A1c, fasting glucose and post-meal glucose. Then it pulled ahead on lipids: by week 13, triglycerides and total cholesterol were significantly lower in the berberine group. In a second arm, 48 poorly-controlled diabetics on berberine saw A1c drop from 8.1% to 7.3% and fasting insulin fall 28%.

A later meta-analysis of 37 studies and 3,048 patients found berberine did not increase adverse events or the risk of hypoglycemia. Metformin, by contrast, carries a black-box risk of lactic acidosis.

→ Read the full article: Berberine Outshines Metformin for Diabetes

4. Saffron vs. Prozac and Lexapro — Depression, OCD, Postpartum Depression

The trials: Six separate head-to-head studies. In a 2016 double-blind trial, 30 mg/day of saffron matched 40 mg of fluoxetine for postpartum depression over six weeks. A 60-patient, 8-week trial found saffron equal to fluoxetine for OCD, with “many fewer” adverse effects. Additional trials found no difference against 60 mg fluoxetine for major depression and panic disorder.

The standout: A 2020 study of 54 patients found 15 mg of saffron produced significantly greater reductions in Hamilton Depression scores — and higher response and remission rates — than 10 mg of escitalopram (Lexapro).

A 2025 meta-analysis of eight RCTs confirmed it: saffron is as effective as SSRIs for depression, with fewer adverse events. The spice in your paella is running even with — and sometimes ahead of — the most prescribed class of psychiatric drugs on earth.

→ Read the full article: 6 Studies on Saffron Put Prozac to Shame

5. Honey vs. Dextromethorphan — Children’s Nighttime Cough

The trial: Children with upper respiratory infections were given buckwheat honey, honey-flavored dextromethorphan (the “DM” in Robitussin DM, Mucinex DM, Vicks Formula 44), or nothing before bed. Parents rated cough frequency, severity and sleep quality. Archives of Pediatrics & Adolescent Medicine, 2007.

The result: Honey scored best on every measure. Parents rated cough frequency 1.89 points better after honey, 1.39 after DM, and 0.92 with nothing. The quietly damning finding: dextromethorphan was not statistically better than no treatment on any outcome.

Even the CDC now advises honey for cough in anyone over one year old. The multi-billion-dollar cough syrup aisle has still not gotten the memo.

→ Read the full article: 5 Reasons Honey Should Be in Your Medicine Chest · Study abstract

6. Turmeric vs. Ibuprofen and Naproxen — Knee Osteoarthritis

 

The trials: A Thai study gave 367 knee osteoarthritis patients either 1,500 mg/day of turmeric extract or 1,200 mg/day of ibuprofen for four weeks. Separately, a 2022 double-blind RCT in Phytotherapy Research gave 60 patients either 500 mg naproxen twice daily or a capsule of turmeric extract, gingerols and piperine twice daily for a month.

The result: Turmeric matched ibuprofen for pain relief and function, with 96–97% patient satisfaction in both groups — but fewer gastrointestinal side effects. The turmeric-ginger-pepper formula relieved pain and inflammation on par with naproxen, with patients rating it equal or better on tolerability, and no adverse effects.

NSAIDs are linked to thousands of GI-bleed deaths a year. Turmeric has a 4,000-year safety record and over 900 documented health benefits in our database.

→ Read the full article: Spice-Based Relief for Aching Joints Beats Dangerous NSAID

7. Ginger vs. Mefenamic Acid and Ibuprofen — Menstrual Pain

 

The trials: 122 women with moderate-to-severe dysmenorrhea took either 250 mg of ginger every six hours or the NSAID mefenamic acid every eight hours, across two menstrual cycles. An earlier trial of 150 women compared 250 mg ginger four times daily against both mefenamic acid and ibuprofen for three days.

The result: Ginger reduced pain “significantly and equally” to the drug in the first trial — roughly half the women in each group went from moderate/severe to mild. In the second, the authors concluded flatly that ginger is as effective as the drugs.

The difference is what comes with it: NSAIDs raise the risk of ulcers, bleeding and cardiovascular events. Ginger raises the risk of nothing in particular.

→ Read the full article: Herbal Research Update for Women’s Health · Eight Unexpected Health Benefits of Ginger

8. Echinacea + Elderberry vs. Tamiflu — Influenza

 

The trial: Double-blind comparison of an Echinacea purpurea and elderberry blend against oseltamivir (Tamiflu), the world’s best-selling flu drug. Current Therapeutic Research, 2015.

The result: By day five, the herbal blend was already slightly ahead. By day ten, 90.1% of the herb group had recovered versus 84.8% on Tamiflu — with fewer complications and fewer side effects. Elderberry alone has repeatedly been shown to cut flu recovery from 7–8 days to 2–3.

Governments stockpiled billions of dollars of Tamiflu. A Cochrane review later found it shortened flu symptoms by about half a day. Elderberry costs twelve dollars.

→ Read the full article: What You Need to Know to Crush the Cold & Flu

9. Licorice (DGL) vs. Tagamet — Peptic Ulcers

 

The trial: Deglycyrrhizinated licorice (DGL) at 760 mg three times daily versus cimetidine (Tagamet), the first blockbuster acid-blocker, for peptic ulcer healing and relapse.

The result: DGL achieved 91% ulcer healing with an 8.2% relapse rate, versus 12.9% relapse with Tagamet. In the same research roundup, 3,000 mg/day of turmeric achieved 72% ulcer healing at eight weeks — comparable to omeprazole (Prilosec).

Acid-blockers are now linked to dementia, kidney disease, fractures and nutrient malabsorption with long-term use. Licorice root has been treating stomachs since Hippocrates.

→ Read the full article: The Mind Thieves — How 6 Common Medications Are Stealing Our Humanity

10. Colostrum vs. the Flu Shot — Influenza Prevention

 

The trial: Head-to-head comparison of oral colostrum against flu vaccination in both healthy adults and high-risk cardiovascular patients over two months. Clinical and Applied Thrombosis/Hemostasis, 2007.

The result: Healthy adults on colostrum alone averaged 0.33 flu episodes versus 1.1 in the vaccinated-only group — roughly three times more protective. Among the high-risk cardiac patients, the colostrum group had zero hospital admissions; the vaccinated group had multiple hospitalizations and one death. Flu-related costs in the colostrum group were about 30% of the vaccinated group’s. No significant side effects were reported.

Vitamin D, for the record, cut influenza A risk by 59% in children at 1,200 IU/day in a separate RCT. Neither appears in a single public health campaign.

→ Read the full article: Colostrum 3x More Effective Than Flu Vaccines

Honorable Mentions: When “Doing Something Else” Beat the Drug

Not every alternative comes in a capsule. From our long-running piece on non-pill interventions that outperformed pharmaceuticals in head-to-head trials:

• Sudarshan Kriya yoga breathing beat the antidepressant imipramine for depression (Journal of Affective Disorders, 2000).
• Acupuncture beat flunarizine for migraine prevention, with superior tolerability.
• Abdominal aromatherapy massage beat Tylenol for menstrual pain.
• Hypnosis matched Valium for anxiety during embryo transfer, with fewer side effects.
• Blue and red light therapy beat 5% benzoyl peroxide for acne, with no side effects.
• An elemental diet matched high-dose steroids for Crohn’s disease in children — and was superior for supporting their growth.

→ Read the full list: 11 Things Better than Drugs or Supplements for Healing

Why You Have Never Heard Most of This

Every study above is published in a peer-reviewed journal and sits in the National Library of Medicine. None of it is hidden. It is simply unfindable — buried in a haystack of tens of millions of papers, with no one paid to surface it, and, since 2021, no longer even filterable under PubMed’s complementary-and-alternative-medicine category, which was quietly removed.

That is why GreenMedInfo exists. We have spent seventeen years indexing this research — 1.4 million studies and counting, hand-mapped to over 16,000 substances, conditions and mechanisms — and keeping it free to search. In 2020 they tried to take it offline. It’s still here. It’s still yours.

If any of this was new to you, that is the whole problem — and the whole reason to search the archive, share this piece, and bring one of these studies to your next doctor’s appointment.

No próximo dia 17 de outubro, a dança volta a ser o centro das atenções em Lagoa com a realização da 15.ª edição do "Lagoa a Dançar".

O conteúdo Lagoa vai dançar aparece primeiro em Algarve Marafado.

No food for a starving population, arresting the groom at a wedding for throwing stones: Israeli cruelty knows no bounds. Get informed here.

From 'birthing persons' to 'white tears' and 'zero tolerance', woke jargon is baffling by design. In the Mail, Andrew Doyle offers an A to Z guide to decoding the language of wokeness.

The post The A-Z of Woke: Your Essential Guide to the Language of the Permanently Offended appeared first on The Daily Sceptic.

The European Parliament’s debate on Monday, October 5th, comes at an awkward moment for Brussels. After years of confrontation with Viktor Orbán, the European Commission now believes Hungary has done enough to justify releasing €4.2 billion in cohesion funding and restoring full access to Erasmus+ and Horizon Europe.

The question before MEPs is therefore deceptively simple: have the conditions really been met, or has Brussels simply found a convenient political moment to declare victory?

The answer matters well beyond Hungary. The original dispute was not some abstract quarrel over Brussels etiquette. In 2022, the EU suspended €6.3 billion in Hungarian cohesion funding after identifying deficiencies in public procurement, conflicts of interest, corruption controls and the effectiveness of prosecutorial action. The conditionality mechanism was deliberately designed to make access to EU taxpayers’ money dependent upon safeguards for the rule of law and the protection of the EU budget.

That principle is important. If membership of the EU means anything, it cannot mean that governments receive billions regardless of whether public money is properly administered.

But Hungary has changed politically. Viktor Orbán’s 16-year rule ended with Péter Magyar’s decisive election victory in April. Magyar campaigned partly on repairing Hungary’s relationship with Brussels and unlocking the billions frozen during the Orbán years. His government subsequently notified the Commission that it had implemented the required reforms.

The Commission has now accepted that argument — albeit partially. Its September 23rd proposal says Hungary has addressed the rule-of-law breaches affecting the EU budget, citing improvements in public procurement, the anti-corruption framework, prevention of conflicts of interest and prosecutorial effectiveness. If the Council approves the proposal, €4.2 billion in cohesion commitments will be reinstated and Hungarian students and researchers will regain full access to Erasmus+ and Horizon Europe.

That is a substantial political prize for Magyar, and a substantial test for the EU.

The danger for Brussels is obvious. Having spent years insisting that European money must not subsidise corruption or institutional capture, the Commission cannot now appear to have changed the rules simply because a more congenial government has arrived in Budapest.

There is, however, an equally serious danger on the other side. If Hungary has genuinely implemented the reforms demanded by Brussels, continuing to withhold money would make the conditionality mechanism look less like a defence of European values and more like a political punishment system. That would be profoundly damaging. Rules that apply only to governments Brussels likes are not rules at all.

This is why Monday’s debate matters – and the €4.2 billion is only part of the story.

The Commission has made clear that other Hungarian funds remain blocked. Around €3.5 billion is affected by a separate mechanism, including approximately €2.7 billion linked to horizontal conditions concerning the EU Charter of Fundamental Rights, including academic freedom, LGBTI rights and asylum.

Meanwhile, Hungary is still seeking access to roughly €10 billion under the Recovery and Resilience Facility. The new Hungarian recovery plan includes measures on anti-corruption, public procurement, transparency, judicial independence and stakeholder participation, with payments tied to the achievement of specific milestones.

So this is not a clean victory for either side.

For Magyar, the release of €4.2 billion demonstrates that his strategy of accommodation with Brussels is delivering tangible results. For the Commission, it provides an opportunity to demonstrate that conditionality can work: reforms are made, the Commission verifies them, and money is released.

But the real test will come afterwards. Brussels must monitor whether the reforms survive political pressure. Anti-corruption bodies must remain genuinely independent. Public procurement must be transparent. Prosecutorial safeguards must work in practice rather than merely on paper. And the judiciary must be capable of challenging the government when necessary.

That is where the European Parliament should concentrate its fire. The temptation will be to turn Monday’s debate into another referendum on Viktor Orbán. That would be yesterday’s argument. Orbán has gone. The more important question is whether Hungary’s new government has actually dismantled the machinery that generated the dispute.

There is a wider lesson here for the European Union.

Conditionality can only work if Brussels is prepared both to withhold money when standards are breached and to release it when standards are met. Anything else undermines the credibility of the entire system.

The Commission says Hungary has crossed that threshold. The Council must now decide whether it agrees.

MEPs should therefore resist both triumphalism and cynicism, if the reforms are real, Hungary should get its money.

If they are cosmetic, Brussels should keep the cheque in the drawer.

Brussels Moves to Release €4.2bn to Hungary as Magyar Unwinds Orbán-Era Dispute